Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults.
Breidenbach M, Bader P, Attarbaschi A, Rossig C, Meisel R, Metzler M, Subklewe M, Mueller F, Schlegel PG, Teichert von Lüttichau I, Bourquin JP, Escherich G, Cario G, Lang P, Coffey R, von Stackelberg A, Willier S, Strahm B, Peters C, Feuchtinger T. Breidenbach M, et al. Among authors: bader p. J Hematol Oncol. 2025 Jan 17;18(1):8. doi: 10.1186/s13045-024-01659-x. J Hematol Oncol. 2025. PMID: 39825416 Free PMC article.
Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.
Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, Ebinger M, Abele M, Holzer U, Döring M, Schulte JH, Bader P, Schlegel PG, Eyrich M, Lang P, Klingebiel T, Handgretinger R. Flaadt T, et al. Among authors: bader p. Cancers (Basel). 2025 Jan 5;17(1):149. doi: 10.3390/cancers17010149. Cancers (Basel). 2025. PMID: 39796776 Free PMC article.
Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients. A multicenter study by EBMT IEWP.
Fekadu-Siebald J, Salzmann-Manrique E, Heusel JR, Willasch A, Hauck F, Gonzalez-Granado LI, Chavoshzadeh Z, Sharafian S, Cuntz F, Baris S, Finocchi A, Algeri M, Sherkat R, Klaudel-Dreszler M, Zeidler C, Bellanné-Chantelot C, Kindle G, Beaupain B, Paillard C, Seidel MG, Bader P, Albert MH, Neven B, Donadieu J, Bakhtiar S. Fekadu-Siebald J, et al. Among authors: bader p. Blood Adv. 2025 Jan 7:bloodadvances.2024014344. doi: 10.1182/bloodadvances.2024014344. Online ahead of print. Blood Adv. 2025. PMID: 39775668
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann JH, Seidl C, Schwäble J, Bug G, Ullrich E. Kayser S, et al. Among authors: bader p. Front Immunol. 2024 Dec 16;15:1413927. doi: 10.3389/fimmu.2024.1413927. eCollection 2024. Front Immunol. 2024. PMID: 39737173 Free PMC article.
COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM.
Kałwak K, Moser LM, Pötschger U, Bader P, Kleinschmidt K, Meisel R, Dalle JH, Yeşilipek MA, Balduzzi AC, Kriván G, Goussetis E, Staciuk R, Sedlacek P, Pichler H, Svec P, Gabriel M, Güngör T, Bilic E, Buechner J, Renard M, Vettenranta K, Ifversen M, Diaz-de-Heredia C, Stein J, Toporski J, Bierings MB, Peters C, Ansari M, Locatelli F. Kałwak K, et al. Among authors: bader p. Blood Adv. 2024 Nov 27:bloodadvances.2024014548. doi: 10.1182/bloodadvances.2024014548. Online ahead of print. Blood Adv. 2024. PMID: 39602342
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials.
Kalwak K, Vora A, Bader P, Burkhardt B, Corbacioglu S, Drabko K, Gozdzik J, Greil J, Gruhn B, Patrick K, Schulz A, Sedlacek P, Styczynski J, Mielcarek-Siedziuk M, Locatelli F, Reinhardt D, Schlegel PG, Baumgart J, Kehne J, Li X, Beier R. Kalwak K, et al. Among authors: bader p. Br J Clin Pharmacol. 2024 Nov 19. doi: 10.1111/bcp.16339. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 39563212
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z. Ortí G, et al. Among authors: bader p. Leukemia. 2024 Nov 19. doi: 10.1038/s41375-024-02467-5. Online ahead of print. Leukemia. 2024. PMID: 39562721
A Rare Case of Hyponatremia Caused by Urinary Retention.
Mahnič O, Bader P. Mahnič O, et al. Among authors: bader p. Eur J Case Rep Intern Med. 2024 Oct 24;11(11):004945. doi: 10.12890/2024_004945. eCollection 2024. Eur J Case Rep Intern Med. 2024. PMID: 39525435 Free PMC article.
Eight induced pluripotent stem cell lines (iPSCs) derived from two patients with Leukocyte adhesion deficiency Type I (LAD I) with mutations in the ITGB2 gene.
Fekadu-Siebald J, Fuchs NV, Zahn S, Rommel MGE, Schenk F, Huenecke S, Bremm M, Kreyenberg H, Kuci Z, Jacobsen EM, Hoenig M, Schwarz K, Bader P, Modlich U, König R, Bakhtiar S. Fekadu-Siebald J, et al. Among authors: bader p. Stem Cell Res. 2024 Dec;81:103598. doi: 10.1016/j.scr.2024.103598. Epub 2024 Oct 24. Stem Cell Res. 2024. PMID: 39522300 Free article.
594 results